What drove the significant increase in net revenues for the quarter?

Net revenues grew 18% (22% on a constant currency basis) to $5.96 billion. This growth was primarily fueled by the strong performance of HUMIRA, both in the U.S. and internationally, and the inclusion of IMBRUVICA revenues following the Pharmacyclics acquisition. Growth from VIEKIRA, Creon, and Duodopa also contributed positively.

What was the impact of the Venezuelan currency devaluation on the company's results?

AbbVie recorded a significant foreign exchange loss of $298 million in the first quarter of 2016 related to the devaluation of its net monetary assets denominated in the Venezuelan bolivar. This negatively impacted net earnings and diluted EPS.

How is AbbVie managing its capital and returning value to shareholders?

The company generated strong operating cash flow of $2.1 billion in the quarter. This allowed for substantial dividend payments of $924 million to shareholders and the settlement of $300 million in share repurchases. AbbVie also continues to authorize share repurchase programs, demonstrating a commitment to shareholder returns.

What are the key strategic initiatives and future growth drivers for AbbVie?

AbbVie is focused on growing revenues through existing on-market products like HUMIRA and IMBRUVICA, expanding margins, investing in its pipeline (immunology, oncology, virology), and augmenting its pipeline through strategic licensing and acquisitions. The recent announcements regarding the acquisition of Stemcentrx and the collaboration with Boehringer Ingelheim for risankizumab highlight this strategic focus on expanding its oncology and immunology portfolios.

ABBV 10-Q Quarterly Report Q1 FY2016 — Revenue, Net Income, EPS

Summary

AbbVie Inc. reported strong financial results for the first quarter of 2016, with net revenues reaching $5.96 billion, an increase of 18% (22% on a constant currency basis) compared to the same period last year. This growth was primarily driven by the robust performance of its key products, HUMIRA and the recently acquired IMBRUVICA, along with contributions from VIEKIRA and other growth brands. Diluted earnings per share stood at $0.83, reflecting both operational strength and the impact of certain one-time items, including a significant foreign exchange loss related to Venezuela. The company demonstrated effective cost management, with selling, general, and administrative expenses as a percentage of net revenue decreasing due to strong revenue leverage, even as R&D investments continued to support a robust pipeline. AbbVie also generated substantial operating cash flow of $2.1 billion, enabling the company to return capital to shareholders through dividends and share repurchases, and to strategically invest in future growth. Significant post-quarter acquisitions and agreements, including the acquisition of Stemcentrx and a collaboration with Boehringer Ingelheim, highlight AbbVie's commitment to expanding its pipeline and therapeutic offerings, particularly in oncology.

Financial Highlights

52 data points

Beta

Revenue

$5.96B

0.8% Gross Margin

Net Income

$1.35B

0.2% Net Margin

EPS (Diluted)

$0.83

Total Assets

$53.72B

Cash & Equivalents

$7.56B

Free Cash Flow

$2.01B

Financial Statements

Beta

Revenue	$5.96B
Cost of Revenue	$1.37B
Gross Profit	$4.59B
SG&A Expenses	$1.35B
Operating Expenses	$3.68B
Operating Income	$2.28B
Interest Expense	$215.00M
Net Income	$1.35B
EPS (Basic)	$0.83
EPS (Diluted)	$0.83
Shares Outstanding (Basic)	1.62B
Shares Outstanding (Diluted)	1.63B

Key Highlights

1Net revenues increased by 18% (22% constant currency) to $5.96 billion, driven by strong performance in HUMIRA and IMBRUVICA.
2Diluted earnings per share (EPS) were $0.83, demonstrating solid profitability despite a significant $298 million foreign exchange loss related to Venezuela.
3Operating cash flow was robust at $2.1 billion, supporting dividend payments ($924 million) and share repurchases ($300 million settled).
4Gross margin as a percentage of net revenue decreased to 77% from 81% due to higher amortization expense from the Pharmacyclics acquisition and inventory step-up.
5Selling, General & Administrative (SG&A) expenses as a percentage of net revenue decreased to 23% from 29%, reflecting strong revenue leverage.
6Research and Development (R&D) expenses increased 17% to $946 million, reflecting continued investment in the pipeline and post-acquisition R&D from Pharmacyclics.
7Subsequent to the quarter, AbbVie announced significant strategic moves, including the acquisition of Stemcentrx for approximately $5.8 billion and a collaboration with Boehringer Ingelheim for risankizumab, signaling a strong focus on pipeline expansion, particularly in oncology.

AbbVie Inc. Quarterly Report for Q1 Ended Mar 31, 2016

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions